Thailand Approves New Oral Antibiotic for Gonorrhoea Treatment Following US Approval
Thailand's Food and Drug Administration has approved Nuzolvence (zoliflodacin), a first-in-class oral antibiotic for treating uncomplicated urogenital gonorrhoea in adults and children over 12 years weighing at least 35 kg. Developed through a public-private partnership involving Dr. Reddy's Laboratories, GARDP, and Innoviva Specialty Therapeutics, the drug addresses multidrug-resistant strains. Thailand is the second country after the US to approve zoliflodacin, marking a significant step in combating antibiotic-resistant gonorrhoea globally.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (68/100). Lens Score 54/100.
Outlets measured: thehindu, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (62–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 27 Jul, 09:41 am. Other outlets followed.
- 1